Bristol Myers Squibb Reveals Promising Data for KarXT, a Potential Treatment for Schizophrenia
A combination of data from the EMERGENT-4 trial and pooled data from the EMERGENT program showed the promise of KarXT (xanomeline-trospium) in providing symptom improvement for people with schizophrenia.
